FXR
Farnesoid X Receptor (FXR) is a nuclear receptor that plays a key role in the regulation of bile acid homeostasis, lipid metabolism, and glucose regulation. FXR is a potential therapeutic target for treating liver diseases, metabolic disorders, and cardiovascular diseases. FXR inhibitors can modulate these pathways, offering insights into disease mechanisms and therapeutic strategies. At CymitQuimica, we provide a range of FXR inhibitors to support your research in hepatology, metabolism, and drug development.
Found 62 products of "FXR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ursodeoxycholic acid
CAS:Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5),inhibits cholesterol absorption. High-Quality, Low-Cost!Formula:C24H40O4Purity:99.74% - ≥95%Color and Shape:White - Almost White Solid PowderMolecular weight:392.57LY2562175
CAS:LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).Formula:C28H27Cl2N3O4Purity:99.16% - 99.78%Color and Shape:SolidMolecular weight:540.44Ref: TM-T15806
1mg99.00€5mg215.00€10mg349.00€25mg700.00€50mg1,108.00€100mg1,485.00€200mg2,008.00€1mL*10mM (DMSO)255.00€Chenodeoxycholic acid
CAS:Chenodeoxycholic acid (CDCA) is a bile acid that inhibits 11β-HSD2 with an IC50 value of 22 mM. High-Quality, Low-Cost!
Formula:C24H40O4Purity:99.70% - 99.93%Color and Shape:White - Almost White Solid PowderMolecular weight:392.57FXR agonist 11
CAS:FXR agonist11 (Compound 14) is an FXR activator with an EC50 of 1.2 μM and a maximal effect of 73.7%. It significantly increases GSH levels in the liver and is used to study drug-induced liver injury.Formula:C18H16N2O5Color and Shape:SolidMolecular weight:340.33Alismanol M
CAS:Alismanol M: FXR agonist, EC50 of 50.25 μM, from Alisma orientale, for cholestasis & NASH research.Formula:C30H48O6Color and Shape:SolidMolecular weight:504.7ZLY28
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1.Formula:C29H23Cl2NO4Purity:98%Color and Shape:SolidMolecular weight:520.4LH10
LH10 is an FXR agonist based on fexaramine, with an EC50 of 0.14 μM. It offers hepatoprotective effects, mitigating conditions such as cholestasis induced by alpha naphthylisothiocyanate (ANIT), acute liver injury caused by APAP, and non-alcoholic steatohepatitis (NASH).Formula:C34H33N3O2Color and Shape:SolidMolecular weight:515.64LZ-007
CAS:LZ-007 is an agonist of the Farnesoid X receptor (FXR), with an EC50 of 51 nM as determined by TR-FRET assay, and an EC50 of 76 nM in HepG2 cells. It exhibits favorable pharmacokinetic properties in SD rats and can improve metabolic dysfunction-associated steatohepatitis induced by high-fat diets and CCl4 in mice.Formula:C27H29F3N2O5Color and Shape:SolidMolecular weight:518.53Fexarene
CAS:Fexarene is a non-steroidal FXR agonist.Formula:C32H33NO3Purity:98%Color and Shape:SolidMolecular weight:479.62FXR agonist 10
FXR agonist10 (Compound 27) acts as an agonist for FXR with an EC50 of 14.26 μM. It increases the expression of SHP and BSEP proteins while decreasing the expression of NTCP and CYP7A1 proteins. Additionally, FXR agonist10 has been shown to ameliorate ANIT-induced cholestasis in mouse models.Formula:C15H22O4Color and Shape:SolidMolecular weight:266.33Nuclear Receptor Compound Library
A unique collection of 531 nuclear receptor signaling targeted compounds for high throughput and high content screening;
Color and Shape:Odour SolidFXR agonist 5
CAS:FXR agonist 5 is an FXR agonist used in the study of liver diseases or diseases mediated by metabolic inflammation.Formula:C40H53N5O5Purity:99.74%Color and Shape:SolidMolecular weight:683.88FXR antagonist 2
CAS:Compound A-26, a diarylamide FXR blocker, may aid hyperlipidemia and diabetes type 2 research.Formula:C22H26Cl2N2O2Color and Shape:SolidMolecular weight:421.36Tauro-β-muricholic acid sodium
CAS:Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM).Formula:C26H44NNaO7SPurity:98%Color and Shape:SolidMolecular weight:537.69FXR/TGR5 agonist 1
CAS:FXR/TGR5 agonist 1 acts as an agonist on both FXR and TGR5 receptors and is utilized for treating fatty liver disease.Formula:C31H32ClN3O3Color and Shape:SolidMolecular weight:530.07F44-A13
CAS:F44-A13 is an orally active, highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. It optimizes cholesterol metabolism and reduces activity by inducing CYP7A1 expression, lowering cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) levels in mouse models. F44-A13 is applicable for studying metabolic diseases associated with lipid disorders [1].Formula:C28H40N4O5SMolecular weight:544.71NR1H4 Protein, Mouse, Recombinant (His)
NR1H4 Protein, Mouse, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 27.80 kDa.Color and Shape:Lyophilized PowderMolecular weight:27.80 kDa (predicted)Ref: TM-TMPY-06756
5µg109.00€10µg174.00€20µg289.00€50µg576.00€100µg1,017.00€200µg1,718.00€500µg4,207.00€NDB
CAS:NDB is a hFXRα antagonist that inhibits GW4064-stimulated FXR/RXR interactions in primary mouse hepatocytes.NDB is used in the study of diabetes.Formula:C26H28Cl2N2O2Purity:98.94%Color and Shape:SolidMolecular weight:471.42FXR agonist 3
FXR agonist 3 is an anti NASH compound with anti-fibrotic and active properties that inhibits the expression of COL1A1, TGF-β1, α-SMA and TIMP1.Formula:C28H28BrNO4Purity:95.04%Color and Shape:SolidMolecular weight:521.12NR1H4 Protein, Human, Recombinant (His)
NR1H4 Protein, Human, Recombinant (His) is expressed in E.Color and Shape:Lyophilized PowderMolecular weight:27.83 kDa (predicted)Ref: TM-TMPY-06768
5µg110.00€10µg177.00€20µg289.00€50µg576.00€100µg1,007.00€200µg1,700.00€500µg3,631.00€
